Free Trial
NASDAQ:VYNE

VYNE Therapeutics (VYNE) Stock Price, News & Analysis

VYNE Therapeutics logo
$1.33 -0.09 (-6.34%)
Closing price 04:00 PM Eastern
Extended Trading
$1.38 +0.05 (+3.76%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About VYNE Therapeutics Stock (NASDAQ:VYNE)

Key Stats

Today's Range
$1.28
$1.46
50-Day Range
$0.89
$1.77
52-Week Range
$0.85
$4.30
Volume
644,775 shs
Average Volume
225,421 shs
Market Capitalization
$20.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25
Consensus Rating
Buy

Company Overview

VYNE Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

VYNE MarketRank™: 

VYNE Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 449th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    VYNE Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    VYNE Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about VYNE Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for VYNE Therapeutics are expected to decrease in the coming year, from ($0.97) to ($1.05) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of VYNE Therapeutics is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of VYNE Therapeutics is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    VYNE Therapeutics has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about VYNE Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.46% of the float of VYNE Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    VYNE Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in VYNE Therapeutics has recently increased by 45.64%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    VYNE Therapeutics does not currently pay a dividend.

  • Dividend Growth

    VYNE Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.46% of the float of VYNE Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    VYNE Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in VYNE Therapeutics has recently increased by 45.64%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    VYNE Therapeutics has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for VYNE Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for VYNE on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, VYNE Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of VYNE Therapeutics is held by insiders.

  • Percentage Held by Institutions

    83.78% of the stock of VYNE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about VYNE Therapeutics' insider trading history.
Receive VYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYNE Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

VYNE Stock Analysis - Frequently Asked Questions

VYNE Therapeutics' stock was trading at $3.35 on January 1st, 2025. Since then, VYNE shares have decreased by 60.3% and is now trading at $1.33.

VYNE Therapeutics Inc. (NASDAQ:VYNE) announced its quarterly earnings data on Thursday, May, 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.09. The business earned $0.20 million during the quarter, compared to analysts' expectations of $0.05 million. VYNE Therapeutics had a negative net margin of 6,974.55% and a negative trailing twelve-month return on equity of 71.89%.

VYNE Therapeutics's stock reverse split on the morning of Monday, February 13th 2023.The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that VYNE Therapeutics investors own include NIO (NIO), Tesla (TSLA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA).

Company Calendar

Last Earnings
5/08/2025
Today
7/14/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VYNE
CIK
1566044
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$4.50
Potential Upside/Downside
+356.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.99)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.83 million
Net Margins
-6,974.55%
Pretax Margin
-6,969.42%
Return on Equity
-71.89%
Return on Assets
-58.94%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.47
Quick Ratio
4.47

Sales & Book Value

Annual Sales
$500 thousand
Price / Sales
41.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.53 per share
Price / Book
0.39

Miscellaneous

Outstanding Shares
15,210,000
Free Float
14,480,000
Market Cap
$20.84 million
Optionable
Not Optionable
Beta
1.78
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:VYNE) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners